Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.

Literature DB >> 20395429

The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.

Aiden Haghikia¹, Ralf Gold.

Abstract

This commentary discusses the non-immune effects of fingolimod on neuroimmunological diseases.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2010 PMID： 20395429 PMCID： PMC2877822 DOI： 10.2353/ajpath.2010.100200

Source DB: PubMed Journal: Am J Pathol ISSN： 0002-9440 Impact factor: 4.307

16 in total

1. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors: Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal: Science Date: 2002-03-28 Impact factor: 47.728

2. The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

Authors: Volker Brinkmann; Michael D Davis; Christopher E Heise; Rainer Albert; Sylvain Cottens; Robert Hof; Christian Bruns; Eva Prieschl; Thomas Baumruker; Peter Hiestand; Carolyn A Foster; Markus Zollinger; Kevin R Lynch
Journal: J Biol Chem Date: 2002-04-19 Impact factor: 5.157

3. Subtype-specific oligodendrocyte dynamics in organotypic culture.

Authors: Michael Haber; Sandrine Vautrin; Elizabeth J Fry; Keith K Murai
Journal: Glia Date: 2009-07 Impact factor: 7.452

4. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

Authors: Veronique E Miron; Samuel K Ludwin; Peter J Darlington; Andrew A Jarjour; Betty Soliven; Timothy E Kennedy; Jack P Antel
Journal: Am J Pathol Date: 2010-04-22 Impact factor: 4.307

5. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors: Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245

6. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors: Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245

Review 7. The alliance of sphingosine-1-phosphate and its receptors in immunity.

Authors: Juan Rivera; Richard L Proia; Ana Olivera
Journal: Nat Rev Immunol Date: 2008-10 Impact factor: 53.106

8. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum.

Authors: A M Ghoumari; C Ibanez; M El-Etr; P Leclerc; B Eychenne; B W O'Malley; E E Baulieu; M Schumacher
Journal: J Neurochem Date: 2003-08 Impact factor: 5.372

2. S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2/4-NFκB signalling.

Authors: Yin-Feng Dong; Ruo-Bing Guo; Juan Ji; Lu-Lu Cao; Ling Zhang; Zheng-Zhen Chen; Ji-Ye Huang; Jin Wu; Jun Lu; Xiu-Lan Sun
Journal: J Cell Mol Med Date: 2018-03-13 Impact factor: 5.310

2 in total